KAS
SPRY icon

Kestra Advisory Services’s ARS Pharmaceuticals SPRY Stock Holding History

Kestra Advisory Services’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,920
Closed -$329K – 3366
2026
Q1 		$329K Buy
40,920
+37,450
+1,079% +$359K ﹤0.01% 2546
2025
Q4 		$40.4K Sell
3,470
-45,729
-93% -$445K ﹤0.01% 4081
2025
Q3 		$494K Buy
49,199
+15,439
+46% +$222K ﹤0.01% 2081
2025
Q2 		$589K Buy
33,760
+2,281
+7% +$32.9K ﹤0.01% 1852
2025
Q1 		$396K Buy
+31,479
New +$379K ﹤0.01% 1976

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Kestra Advisory Services's SPRY Position: Q2 2026 in Review

Kestra Advisory Services sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 40,920 shares — an estimated $329K sold.

Kestra Advisory Services first reported a position in SPRY in Q1 2025 and held it in 5 quarters. The position peaked at $589K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Kestra Advisory Services reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 40,920 ARS Pharmaceuticals shares in Q2 2026, an estimated $329K.
  • Kestra Advisory Services first reported a position in ARS Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • Kestra Advisory Services's ARS Pharmaceuticals position peaked at $589K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.